Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 495

1.

Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.

Neogi U, Rao SD, Bontell I, Verheyen J, Rao VR, Gore SC, Soni N, Shet A, Schülter E, Ekstrand ML, Wondwossen A, Kaiser R, Madhusudhan MS, Prasad VR, Sonnerborg A.

AIDS. 2014 Aug 6. [Epub ahead of print]

PMID:
25102091
[PubMed - as supplied by publisher]
2.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD.

Br J Haematol. 2014 Jul 4. doi: 10.1111/bjh.13008. [Epub ahead of print]

PMID:
24995683
[PubMed - as supplied by publisher]
3.

High rates of growth recorded for hawksbill sea turtles in Anegada, British Virgin Islands.

Hawkes LA, McGowan A, Broderick AC, Gore S, Wheatley D, White J, Witt MJ, Godley BJ.

Ecol Evol. 2014 Apr;4(8):1255-66. doi: 10.1002/ece3.1018. Epub 2014 Mar 13.

PMID:
24834324
[PubMed]
Free PMC Article
4.

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Tallman MS, Gore SD; Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup.

Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.

PMID:
24712482
[PubMed - in process]
5.

Heparin surfaces: Impact of immobilization chemistry on hemocompatibility and protein adsorption.

Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J.

J Biomed Mater Res B Appl Biomater. 2014 Apr 8. doi: 10.1002/jbm.b.33154. [Epub ahead of print]

PMID:
24711209
[PubMed - as supplied by publisher]
6.

Head and neck multidisciplinary team meetings: Effect on patient management.

Brunner M, Gore SM, Read RL, Alexander A, Mehta A, Elliot M, Milross C, Boyer M, Clark JR.

Head Neck. 2014 Apr 7. doi: 10.1002/hed.23709. [Epub ahead of print]

PMID:
24710807
[PubMed - as supplied by publisher]
7.

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS.

J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24.

PMID:
24663049
[PubMed - indexed for MEDLINE]
8.

Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

Zeidan AM, Prebet T, Saad Aldin E, Gore SD.

Expert Rev Hematol. 2014 Apr;7(2):191-4. doi: 10.1586/17474086.2014.891437. Epub 2014 Feb 24.

PMID:
24559255
[PubMed - in process]
Free PMC Article
9.

Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma.

Gore SM, Crombie AK, Batstone MD, Clark JR.

Head Neck. 2014 Feb 15. doi: 10.1002/hed.23626. [Epub ahead of print]

PMID:
24532246
[PubMed - as supplied by publisher]
10.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Br J Haematol. 2014 May;165(4):497-503. doi: 10.1111/bjh.12775. Epub 2014 Feb 14.

PMID:
24528179
[PubMed - indexed for MEDLINE]
11.

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes.

Seymour JF, Bennett JM, List AF, Mufti GJ, Gore SD, Fenaux P, Santini V, Hetzer J, Songer S, Skikne BS, Beach CL.

Br J Haematol. 2014 Apr;165(1):49-56. doi: 10.1111/bjh.12723. Epub 2014 Jan 28.

PMID:
24467613
[PubMed - indexed for MEDLINE]
12.

Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.

Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD.

Clin Cancer Res. 2014 Mar 1;20(5):1249-58. doi: 10.1158/1078-0432.CCR-13-1453. Epub 2014 Jan 14.

PMID:
24423613
[PubMed - in process]
13.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

PMID:
24362550
[PubMed - in process]
Free PMC Article
14.

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

Fenaux P, Seymour JF, Santini V, Silverman L, Gore S, List A, Sanz G, Mufti GJ, Estey E, Swern AS, Beach CL, Hellstrom-Lindberg E.

Leuk Res. 2014 Feb;38(2):258-62. doi: 10.1016/j.leukres.2013.10.014. Epub 2013 Oct 27.

PMID:
24360612
[PubMed - indexed for MEDLINE]
Free Article
15.

PDBe: Protein Data Bank in Europe.

Gutmanas A, Alhroub Y, Battle GM, Berrisford JM, Bochet E, Conroy MJ, Dana JM, Fernandez Montecelo MA, van Ginkel G, Gore SP, Haslam P, Hatherley R, Hendrickx PM, Hirshberg M, Lagerstedt I, Mir S, Mukhopadhyay A, Oldfield TJ, Patwardhan A, Rinaldi L, Sahni G, Sanz-García E, Sen S, Slowley RA, Velankar S, Wainwright ME, Kleywegt GJ.

Nucleic Acids Res. 2014 Jan;42(Database issue):D285-91. doi: 10.1093/nar/gkt1180. Epub 2013 Nov 27.

PMID:
24288376
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Use of the nasal sidewall island inversion flap for single-stage ala nasi reconstruction: a report of 103 consecutive cases.

Tregaskiss A, Allan J, Gore S, Aldred R.

Plast Reconstr Surg. 2014 Feb;133(2):377-85. doi: 10.1097/01.prs.0000436797.81928.24.

PMID:
24150115
[PubMed - indexed for MEDLINE]
17.

Epidermolysis bullosa: Careful monitoring and no touch principle for anesthesia management.

Saraf SV, Mandawade NJ, Gore SK, Padhye UD, Pereira CS.

J Anaesthesiol Clin Pharmacol. 2013 Jul;29(3):390-3. doi: 10.4103/0970-9185.117112.

PMID:
24106369
[PubMed]
Free PMC Article
18.

Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Zeidan AM, Gore SD.

Expert Rev Hematol. 2013 Oct;6(5):539-42. doi: 10.1586/17474086.2013.827097. Epub 2013 Oct 4.

PMID:
24093972
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Mitchell M, Gore SD, Zeidan AM.

Expert Rev Hematol. 2013 Aug;6(4):397-410. doi: 10.1586/17474086.2013.814456. Review.

PMID:
23991926
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Current therapy of myelodysplastic syndromes.

Zeidan AM, Linhares Y, Gore SD.

Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27. Review.

PMID:
23954262
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk